Stock-PR Reporting

AstraZeneca PLC (NYSE:AZN) announced it has entered into a settlement agreement in its U.S. SEROQUEL XR® patent infringement litigation against Handa Pharmaceuticals, LLC ("Handa") regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR (quetiapine fumarate) extended-release tablets.

Aon Corporation (NYSE:AON) announced its execution of a $450 million Term Credit Agreement (the "Agreement"). The loans incurred under the Agreement will mature on October 1, 2013 and will bear interest at a variable annual rate of Libor plus a margin which varies depending on the Company's public debt ratings.